Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 20/20 | 0.58 |
| ▸ | OGFRL1 | Q5TC84 | 14/20 | 0.58 |
| ▸ | OPRL1 | P41146 | 10/20 | 0.58 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL381361 | 0.88 | OPRM1 (0.58) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| SCHEMBL10038876 | 0.87 | OPRM1 (0.71) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| SCHEMBL158960 | 0.87 | OPRM1 (0.71) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| Citric Acid SCHEMBL4763250 | 0.86 | OPRM1 (0.61) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| SCHEMBL4765365 | 0.85 | OPRM1 (0.63) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| Citric Acid SCHEMBL4765443 | 0.84 | OPRM1 (0.58) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| Cebranopadol SCHEMBL29597164 | 0.81 | OPRM1 (0.77) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| Citric Acid SCHEMBL4436232 | 0.80 | OPRM1 (0.52) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| Citric Acid SCHEMBL1304800 | 0.80 | OPRM1 (0.79) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| Citric Acid SCHEMBL4769200 | 0.78 | OPRM1 (0.62) | OPRM1OGFRL1OPRL1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150342929-A1 | Mixed ORL1/mu-agonists for the Treatment of Pain | GRUENENTHAL GMBH (DE) | 2015-12-03 | — | — | US | claimed |
| EP-2206498-B9 | Mixed ORL1/[mu] agonists for treating pain | GRUENENTHAL GMBH (DE) | 2012-04-18 | — | — | EP | claimed |
| EP-2206498-B1 | Mixed ORL1/[mu] agonists for treating pain | GRUENENTHAL GMBH (DE) | 2012-01-25 | — | — | EP | claimed |
| EP-2081571-B1 | MIXED ORL 1/µ AGONISTS FOR TREATING PAIN | GRUENENTHAL GMBH (DE) | 2010-08-25 | — | — | EP | claimed |
| EP-1725567-B1 | SPIROCYCLIC CYCLOHEXANE DERIVATIVES WITH AFFINITY TO THE ORL-1 RECEPTOR | GRUENENTHAL GMBH (DE) | 2008-03-26 | — | — | EP | claimed |
| US-7332519-B2 | Spirocyclic cyclohexane compounds | GRUENENTHAL GMBH (DE) | 2008-02-19 | — | — | US | claimed |
| US-20050192333-A1 | Spirocyclic cyclohexane compounds | GRUENENTHAL GMBH (DE) | 2005-09-01 | — | — | US | claimed |
| US-20150342929-A1 | Mixed ORL1/mu-agonists for the Treatment of Pain | GRUENENTHAL GMBH (DE) | 2015-12-03 | — | — | US | disclosed |
| US-20110015220-A1 | MIXED ORL1/MU-AGONISTS FOR THE TREATMENT OF PAIN | GRUNENTHAL GMBH (DE) | 2011-01-20 | — | — | US | disclosed |
| US-20080125475-A1 | Mixed ORL1/mu-agonists for the treatment of pain | GRUNENTHAL GMBH (DE) | 2008-05-29 | — | — | US | disclosed |
| US-7332519-B2 | Spirocyclic cyclohexane compounds | GRUENENTHAL GMBH (DE) | 2008-02-19 | — | — | US | disclosed |
| US-20050192333-A1 | Spirocyclic cyclohexane compounds | GRUENENTHAL GMBH (DE) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015220-A1 | MIXED ORL1/MU-AGONISTS FOR THE TREATMENT OF PAIN | OPRL1, OPRM1, OPRK1 | OPRM1 2/4885OGFRL1 5/4885OPRL1 1/4885 |
| US-20080125475-A1 | Mixed ORL1/mu-agonists for the treatment of pain | OPRL1, OPRM1, OPRK1 | OPRM1 2/4885OGFRL1 5/4885OPRL1 1/4885 |
| US-20150342929-A1 | Mixed ORL1/mu-agonists for the Treatment of Pain | OPRL1, OPRM1, OPRK1 | OPRM1 2/4885OGFRL1 5/4885OPRL1 1/4885 |
| US-20050192333-A1 | Spirocyclic cyclohexane compounds | OPRL1, OPRK1, OPRD1 | OPRM1 5/4885OGFRL1 6/4885OPRL1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.